A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2220 participants.
Also called NCT01516541
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 2,220 participants
- Sponsor
- Registry
-
NCT01516541 -
2011-001891-21
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Australia, Canada, China, Czechia, Denmark, France, Hungary, Mexico, Netherlands, Poland, Spain, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01516541. Randomized; double masking; primary purpose treatment. Start 2012-01 (registry gives no type); primary completion 2012-07 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease
- Condition
- Cardiovascular Disease, Coronary Heart Disease, Dyslipidemia, Peripheral Arterial Disease (PAD)
- Intervention (Other)
- Background care
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- dalcetrapib
- Lead sponsor
- Hoffmann-La Roche
Record details
- Record id
cardio:ct-nct01516541- Content hash
562fb53e0259fd9470bd568b4d42ec9293c397609bcc11a4a0ffd3cba39bea2f